AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01463488
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Trial: NCT01634906
Drug: Temporary discontinuation of statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
Trial: NCT00423605
Drug: Xyrem®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flexible dosing
Trial: NCT00396292
Drug: Oral iron tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
Trial: NCT01521546
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg tablet, once daily by mouth for 12 months
Trial: NCT01521546
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet by mouth daily for 12 months
Trial: NCT01205204
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
Trial: NCT03977480
Drug: Hemay007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay007 will be orally administered.
Trial: NCT02651636
Drug: myo-inositol,alpha-lipoic acid and folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03977480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02606305
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00154180
Drug: Transdermal estradiol, 50 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
Trial: NCT00154180
Drug: CEE , progesterone, estradiol patch or placebo for each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
Trial: NCT01951846
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV to maintain the blind.
Trial: NCT00107393
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01939197
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01939197
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01834963
Drug: Interferon Alfa、Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks
Trial: NCT01834963
Drug: Cisplatin、Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks
Trial: NCT00593502
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of placebo will be similar to the active drug
Trial: NCT04188587
Drug: 177 Lu-PSMA-I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
Trial: NCT03959553
Drug: GV1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized peptide from hTERT
Trial: NCT03959553
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT01459081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled by mouth, twice daily, for 5 days
Trial: NCT02933866
Drug: DSXS topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment
Trial: NCT01173770
Drug: ADC3680B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC3680B or Placebo for 7 days
Trial: NCT01204242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
Trial: NCT03051711
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules which contain GBT440 drug substance in Swedish Orange
Trial: NCT00147212
Drug: ET 743
RxNorm normalized name: ethanol 0.743 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-743 administered IV by 24-hr infusion every 3 weeks
Trial: NCT04328766
Drug: DWC202005, alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202005, as a single dose
Trial: NCT04328766
Drug: DWP14012 + DWC202005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 and DWC202005, as a single dose
Trial: NCT04328766
Drug: DWP14012 + DWC202005, after multiple doses of DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
Trial: NCT02434978
Drug: IV. PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
Trial: NCT03978403
Drug: M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups
Trial: NCT03978403
Drug: M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches
Trial: NCT02789033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01817829
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00940160
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00940160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02206659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00383890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00618163
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01840371
Drug: Conventional sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation
Trial: NCT01840371
Drug: Experimental sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation
Trial: NCT02169479
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC, Opicapone
Trial: NCT02169479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLC, Placebo
Trial: NCT02169479
Drug: Sinemet® 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release levodopa/carbidopa 100/25 mg
Trial: NCT02456948
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 weeks 200mg/day Minocycline add-on
Trial: NCT02456948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks Placebo add-on
Trial: NCT00425919
Drug: PPM-204
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01835678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once a day for 4 weeks
Trial: NCT02058095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Trial: NCT01502943
Drug: TCM granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Trial: NCT01502943
Drug: Chixiangshen Tongxin granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper.
Trial: NCT01502943
Drug: TCM granule placebo plus western basis treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Trial: NCT01502943
Drug: Western basis treatment
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
Trial: NCT01226797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
Trial: NCT04101357
Drug: BNT411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT04585815
Drug: SEA-TGT
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution in vials
Trial: NCT02612857
Drug: IMO-8400 Dose Group 1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
Trial: NCT02612857
Drug: IMO-8400 Dose Group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
Trial: NCT02612857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline subcutaneous injections once a week for 24 weeks.
Trial: NCT00202488
Drug: H. pylori treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02932943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Trial: NCT00577460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to Pramipexole ER tablets
Trial: NCT00534703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
Trial: NCT01001208
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablets over-encapsulated for blinding
Trial: NCT03574649
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03574649
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT01001208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to methotrexate capsules
Trial: NCT01641445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capusules (sugar pills
Trial: NCT00551005
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01310049
Drug: LEO 32731
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days
Trial: NCT01406678
Drug: isoflurane+sufentanil anesthesia
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Trial: NCT00878995
Drug: Placebo Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Saline) Testosterone given IM once per week.
Trial: NCT00878995
Drug: Testosterone Enanthate 100 MG/ML
RxNorm normalized name: testosterone enanthate 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate 100mg/ml given once per week IM.
Trial: NCT01454284
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02665117
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
Trial: NCT01030965
Drug: GSK573719 125mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mcg once-daily
Trial: NCT01345799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04464460
Drug: TAK-671 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-671 placebo-matching intravenous infusion.
Trial: NCT00469547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% ethanol in emollient gel used as a topical male microbicide
Trial: NCT01750437
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00447681
Drug: ILV-094
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254824
Drug: Xuezhikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang
Trial: NCT02924155
Drug: SJP002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Trial: NCT02924155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Trial: NCT03703063
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by intravenous infusion over 30 minutes.
Trial: NCT01150747
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm once
Trial: NCT02744352
Drug: 20ml bolus of 0.5% ropivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic
Trial: NCT01937390
Drug: Indacterol 300 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation powder
Trial: NCT01937390
Drug: Indacterol 150 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation powder
Trial: NCT04183231
Drug: Anti-caries varnish
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical tooth varnish
Trial: NCT01874951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
Trial: NCT00483496
Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00483496
Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00483496
Drug: V0096 CR vehicle (formula RV3131A-MV1197)
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01214122
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg orally twice daily for 11 days
Trial: NCT00025337
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00025337
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00671749
Drug: clindamycin/benzoyl peroxide gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied once daily in the morning
Trial: NCT00455624
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to standard medical care
Trial: NCT00259610
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: varies
Trial: NCT01569152
Drug: MK-8457 100 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8457 100 mg dosed orally BID
Trial: NCT01569152
Drug: Dose-Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo dosed orally BID
Trial: NCT01569152
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX dosed at the stable dose receive upon study entry
Trial: NCT01766778
Drug: LAF237 (vildagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50mg capsule
Trial: NCT04359095
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
Trial: NCT03392571
Drug: NGC-Triple regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
Trial: NCT03208426
Drug: Clarithromycin (ST14)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
Trial: NCT03208426
Drug: tetracycline (BQ10)
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
Trial: NCT00712920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02346201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
Trial: NCT01681472
Drug: 6R-MTHF (arfolitixorin) 200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus injection
Trial: NCT01681472
Drug: Levoleucovorin 200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus injection
Trial: NCT01681472
Drug: 6R-MTHF (arfolitixorin) 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus injection
Trial: NCT01681472
Drug: Levoleucovorin 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus injection